Acer Therapeutics to Participate in March Virtual Investor Conferences

Rhea-AI Summary

Acer Therapeutics Inc. (Nasdaq: ACER) will present at two virtual conferences in March 2021, focusing on therapies for serious rare diseases. The H.C. Wainwright Global Life Sciences Virtual Conference is scheduled for March 9-10, 2021. Acer's management will also participate in the 33rd Annual Roth Virtual Conference on March 15, 2021, with a panel presentation on therapeutics against SARS-CoV-2 at 12 p.m. Eastern Time. Acer's pipeline includes therapies for urea cycle disorders, vascular Ehlers-Danlos syndrome, and COVID-19.

NEWTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Life Sciences Virtual Conference and the 33^rd Annual Roth Virtual Conference.

Conference:	H.C. Wainwright Global Life Sciences Virtual Conference
Dates:	March 9-10, 2021
Format:	One-on-one virtual meetings
Conference:	33rd Annual Roth Virtual Conference
Format:	Panel Presentation and one-on-one virtual meetings
Panel:	Therapeutics Against SARS-CoV-2
Date:	Monday, March 15, 2021
Time:	12 p.m. Eastern Time
Webcast:	https://acertx.com/investor-relations/events-presentations/

About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms (iVMS); and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. For more information, visit www.acertx.com.

Investor Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 617-430-7578
hans@lifesciadvisors.com

Jim DeNike
Acer Therapeutics Inc.
Ph: 844-902-6100
jdenike@acertx.com

FAQ

When is Acer Therapeutics presenting at the H.C. Wainwright Global Life Sciences Virtual Conference?

Acer Therapeutics will present at the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021.

What is the date and time of Acer Therapeutics' panel presentation at the Roth Virtual Conference?

Acer Therapeutics' panel presentation at the 33rd Annual Roth Virtual Conference is on March 15, 2021, at 12 p.m. Eastern Time.

What topics will Acer Therapeutics discuss at the Roth Virtual Conference?

Acer Therapeutics will discuss therapeutics against SARS-CoV-2 at the Roth Virtual Conference.

What is the focus of Acer Therapeutics as a company?

Acer Therapeutics focuses on developing therapies for serious rare and life-threatening diseases with significant unmet medical needs.

What therapies are included in Acer Therapeutics' pipeline?

Acer's pipeline includes ACER-001 for urea cycle disorders, EDSIVO™ for vascular Ehlers-Danlos syndrome, ACER-801 for induced vasomotor symptoms, and ACER-2820 for COVID-19.